OBJECTIVE: To retrospectively investigate whether disease-modifying therapies (DMTs) exert differential effects on rates of @entity2479 in @entity3780 ( @entity3780 ), as assessed using optical coherence tomography (OCT). METHODS: A total of 402 @entity1 with @entity3780 followed at the Johns Hopkins @entity15 Center who underwent Cirrus- @entity2033 OCT were assessed for eligibility. Inclusion criteria included at least 1 year of OCT follow-up and adherence to a single DMT during the period of follow-up. Combined thickness of the ganglion cell + inner plexiform (GCIP) and other retinal layers was computed utilizing automated macular segmentation. Retinal thickness changes were analyzed using mixed-effects linear regression. RESULTS: The effects of @entity1638 (GA; n = 48), natalizumab (NAT; n = 46), and interferon-b-1a subcutaneously (IFNSC; n = 35) and intramuscularly (IFNIM; n = 28) were assessed. Baseline analyses revealed no significant differences between groups in terms of age, sex, @entity7995 history, or follow-up duration. During follow-up, relative to NAT-treated @entity1 , IFNSC- and GA-treated @entity1 exhibited 0.37  m/y (p < 0.001) and 0.14  m/y (p = 0.035) faster rates of GCIP thinning, respectively, adjusting for the interval between initiation of DMT and OCT monitoring (gap time), age, sex, relapses, and disease duration. In the IFNSC group, GCIP thinning was 1.53  m/y faster during the first year of therapy vs during the time interval afterwards (p < 0.001). CONCLUSIONS: Rates of GCIP @entity194 in @entity1 with @entity3780 vary according to DMT utilization. Our findings support OCT for monitoring neurodegenerative treatment effects in the retina, an easily accessible tissue, and as a practical outcome measure in @entity3780 clinical trials.

Disease-modifying therapies modulate XXXX in @entity15 : A retrospective study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1638 :: ('MESH:C089995', 'Chemical') :: ['glatiramer acetate'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal atrophy'] @entity3780 :: ('MESH:D020529', 'Disease') :: ['relapsing-remitting multiple sclerosis', 'RRMS'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD'] @entity7995 :: ('MESH:D009902', 'Disease') :: ['optic neuritis'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS']
@entity2479 :: (MESH:D012173,Disease) :: ['retinal atrophy']
